ALGOTHERAPEUTIX
15.12.2020 08:17:14 CET | Business Wire | Press release
France-based biotechnology company AlgoTherapeutix, the developer of an innovative topical treatment for chemotherapy-induced peripheral neuropathy (CIPN), announced today it has received approval from the ethics committee and the regulatory authority in the Czech Republic to initiate a Phase 1 clinical trial with ATX01. The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021.
AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. Given a positive outcome of the approved Phase 1 study, the company intends to initiate Phase 2 by the end of 2021.
Stéphane Thiroloix , Founder & CEO of AlgoTherapeutix, says: “I am thrilled by the entry of ATX01 in clinical development as it represents a great step forward towards providing CIPN patients with a response to the crippling pain they endure.”
Over half of cancer patients treated with chemotherapy - over two million patients in the US and Europe - develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. CIPN is a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists and pain specialists.
Over the last two years, AlgoTherapeutix took ATX01 from exploratory prototype to final formulation, established its pharmacological profile, conducted a full pre-clinical toxicology package, and scaled-up manufacturing to enable clinical supply production. In parallel, AlgoTx firmed-up ATX01’s development pathway via a pre-IND consultation with the FDA and obtained an Orphan Drug Designation from the FDA to explore ATX01’s activity in erythromelalgia.
A recent publication in the “Journal of Pain” describes the exploratory pharmacological impact of high-dose topical amitriptyline in CIPN patients along with the mechanism of action supporting its activity (https://doi.org/10.1016/j.jpain.2020.11.002 )
About AlgoTherapeutix
AlgoTx was founded in 2018 by Stéphane Thiroloix and Olivier Bohuon to develop topical treatments for complex pain and was incubated by Paris Biotech Santé. Their lead programme ATX01 is in clinical development in Chemotherapy-Induced Peripheral Neuropathy. More information at www.algotx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005352/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Confirmed as the World’s Leading Food Company for Reputation - Ranking 9th Overall Globally8.4.2026 14:42:00 CEST | Press release
GLOBAL REPTRAK®100 2026For the third consecutive year, Barilla is confirmed as the world’s leading food company in the Global RepTrak® 100 and enters the overall Top 10 of global companies.The Group ranks 9th overall, up 16 positions compared to 2025. For the third year in a row, Barilla is confirmed as the world’s leading company in the food sector for reputation in the Global RepTrak® 100 ranking conducted by RepTrak, which since 1999 has annually analyzed the companies with the strongest reputations worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407912080/en/ In the 2026 ranking, the Group reaches 9th place overall, moving up 16 spots compared to 2025 (ranked at 25th) and entering the global Top 10, confirming the company’s steady reputation‑building journey developed over the years. This result reflects Barilla’s ability to combine product quality, industrial vision and social responsibility – factors that
Adtran launches Ensemble Cloudlet multi‑node to simplify high‑availability edge AI deployments8.4.2026 14:30:00 CEST | Press release
News summary: Enterprises and service providers need resilient, low-latency infrastructure to support emerging edge AI inference Ensemble Cloudlet multi-node creates high-availability edge clouds with distributed storage, starting from just two nodes Open platform with zero-touch deployment runs networking, security and AI workloads, including agentic AI applications Adtran today launched its Ensemble Cloudlet multi‑node solution, a high‑availability edge platform that supports AI inference and agentic AI deployments where low latency, resilience and secure local processing are critical. Removing the complexity and cost barriers that slow modern service and enterprise deployments, the solution creates a single, logical cloud with distributed storage and automated failover, starting with just two nodes. Built on Cloudlet OS and managed through Ensemble EdgeView orchestration, it enables zero-touch deployment and unified lifecycle management, providing a simple, scalable foundation for r
ZincFive Announces Nickel-Zinc Retrofit Kit to Modernize Existing UPS Energy Storage Infrastructure8.4.2026 14:05:00 CEST | Press release
A turnkey, safe, scalable drop-in upgrade for existing UPS systems with a long-life, sustainable alternative to lead-acid ZincFive®, the global leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today announced the NiZn Retrofit Kit, an uninterruptible power supply (UPS) energy storage solution designed to bring the benefits of modern battery chemistry to existing UPS battery systems in mission-critical environments. The NiZn Retrofit Kit will enable data center operators and service providers to replace legacy valve-regulated lead-acid (VRLA) batteries with ZincFive’s long-life, high-performance nickel-zinc technology without requiring cabinet enclosure replacement, system redesign, or operational disruption. As data center power demands continue to increase, operators face growing pressure to improve reliability, reduce lifecycle costs, and meet sustainability targets. At the same time, much of the global UPS energy storage system installed base re
New Research Finds AI Is Now Foundational to Modern Marketing8.4.2026 14:00:00 CEST | Press release
AI’s Impact on Marketing Doubles as Teams Move from Experimentation to Embedded Use NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced its participation in a new marketing research study conducted by Callan Consulting, a Silicon Valley executive marketing consulting firm, joining 18 B2B and B2C technology companies to examine how AI is reshaping modern marketing organizations, marking a clear shift from early experimentation to embedded, enterprise‑wide adoption. According to the State of AI in Technology Marketing 2026 report, based on in‑depth interviews with CMOs and senior marketing leaders at the participating companies, the study finds that AI is becoming rapidly integrated across core marketing teams and workflows—from content development and research to campaign optimization and analytics. As adoption deepens, data quality, accessibility, and governance are emerging as critical priorities. "AI doesn't change what great marketing is supposed to
Sagard and Unigestion Announce Closing of Partnership Transaction8.4.2026 14:00:00 CEST | Press release
Transaction completion marks the formal expansion of a strengthened global platform: Sagard Private Equity Solutions Sagard, a global multi-strategy alternative asset management firm with over $45 billion USD1 in assets under management and Unigestion Private Equity Holding SA (UNG PE), a leading middle market private equity provider, today announced the successful closing of their combination transaction, originally announced in September. Completion of this transaction marks the formal launch of the partnership and the integration of UNG PE into Sagard’s global middle-market private equity platform, Sagard Private Equity Solutions (SPES). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260408374851/en/ “We are thrilled to formally begin our partnership with the Unigestion team,” said Paul Desmarais III, Chairman & CEO of Sagard. “This milestone solidifies our joint commitment to building a global private equity platform pos
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom